Baidu
map

INT J LAB HEMATOL:用于质量控制的材料的可交换性的重要性!

2019-01-26 MedSci MedSci原创

外部质量评价是实验室质量保证的重要组成部分。有时,正常血浆被用来模拟临床样本。但是,重要的是,我们所添加的标准材料应该可以提供类似的结果临床样本(即,是可交换的),以确保可以从EQA演习获得适当的结论。因此,本研究描述了来自英国国家凝血外部质量评估计划(NEQAS BC)的数据,在该计划中,将添加了标准品的样本与来自患者的样本一起进行测试,以探索人造材料的可替代性。正常血浆中加入未分离肝素(UFH

外部质量评价是实验室质量保证的重要组成部分。有时,正常血浆被用来模拟临床样本。但是,重要的是,我们所添加的标准材料应该可以提供类似的结果临床样本(即,是可交换的),以确保可以从EQA演习获得适当的结论。因此,本研究描述了来自英国国家凝血外部质量评估计划(NEQAS BC)的数据,在该计划中,将添加了标准品的样本与来自患者的样本一起进行测试,以探索人造材料的可替代性。正常血浆中加入未分离肝素(UFH)、低分子量肝素(LMWH)、达比加群或利伐沙班。因子VIII (FVIII)缺陷血浆中加入FVIII浓缩物。将添加了标准品的样本和体内病人的材料送到实验室进行检测。对于低分子肝素,从患者血浆中提取的样本与加入肝素的血浆样本的结果一致。对于UFH,相同药物浓度的急骤上升的样本和患者样本之间APTT比率不同,在试剂的排名上没有相关性。利伐沙班和达比加特兰试验的病人和添加了标准品的样本的材料精确度是相当的。然而,一些达比加特兰试剂盒的结果模式在添加了标准品的样本和患者样本之间有所不同。对于FVIII测定,加入添加了标准品的样本和注射后样品的结果具有可比性。如果证明存在可交换性,那么添加了标准品材料即可适用于EQA

本研究数据显示,在血浆中加入利伐沙班、LWMH和一些FVIII浓缩物后,血浆具有可交换性。而对于某些测试,尤其是UFHAPTT,患者和添加了标准品的样本之间的显著差异表明,并非所有测试都可以使用人工样本进行评估。

原始出处:

Ian Jennings Dianne Kitchen Steve Kitchen, The importance of commutability in material used for quality control purposes

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1942465, encodeId=3a3619424654d, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Nov 21 06:38:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069568, encodeId=8974206956885, content=<a href='/topic/show?id=db43384135e' target=_blank style='color:#2F92EE;'>#可交换性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38413, encryptionId=db43384135e, topicName=可交换性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 27 12:38:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863135, encodeId=0fa718631356b, content=<a href='/topic/show?id=afe992396a2' target=_blank style='color:#2F92EE;'>#质量控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92396, encryptionId=afe992396a2, topicName=质量控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 03 13:38:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317455, encodeId=922b131e45504, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Jan 28 12:38:00 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
    2019-11-21 mgqwxj
  2. [GetPortalCommentsPageByObjectIdResponse(id=1942465, encodeId=3a3619424654d, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Nov 21 06:38:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069568, encodeId=8974206956885, content=<a href='/topic/show?id=db43384135e' target=_blank style='color:#2F92EE;'>#可交换性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38413, encryptionId=db43384135e, topicName=可交换性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 27 12:38:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863135, encodeId=0fa718631356b, content=<a href='/topic/show?id=afe992396a2' target=_blank style='color:#2F92EE;'>#质量控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92396, encryptionId=afe992396a2, topicName=质量控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 03 13:38:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317455, encodeId=922b131e45504, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Jan 28 12:38:00 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1942465, encodeId=3a3619424654d, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Nov 21 06:38:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069568, encodeId=8974206956885, content=<a href='/topic/show?id=db43384135e' target=_blank style='color:#2F92EE;'>#可交换性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38413, encryptionId=db43384135e, topicName=可交换性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 27 12:38:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863135, encodeId=0fa718631356b, content=<a href='/topic/show?id=afe992396a2' target=_blank style='color:#2F92EE;'>#质量控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92396, encryptionId=afe992396a2, topicName=质量控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 03 13:38:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317455, encodeId=922b131e45504, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Jan 28 12:38:00 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1942465, encodeId=3a3619424654d, content=<a href='/topic/show?id=851b960646e' target=_blank style='color:#2F92EE;'>#重要性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96064, encryptionId=851b960646e, topicName=重要性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Thu Nov 21 06:38:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2069568, encodeId=8974206956885, content=<a href='/topic/show?id=db43384135e' target=_blank style='color:#2F92EE;'>#可交换性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38413, encryptionId=db43384135e, topicName=可交换性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Feb 27 12:38:00 CST 2019, time=2019-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1863135, encodeId=0fa718631356b, content=<a href='/topic/show?id=afe992396a2' target=_blank style='color:#2F92EE;'>#质量控制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92396, encryptionId=afe992396a2, topicName=质量控制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri May 03 13:38:00 CST 2019, time=2019-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317455, encodeId=922b131e45504, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Mon Jan 28 12:38:00 CST 2019, time=2019-01-28, status=1, ipAttribution=)]
    2019-01-28 fengyi812

相关资讯

冷冷冷!血常规标本也怕冷

2018年12月18日,检验科收到一份“冷”的血常规标本,来自呼吸重症监护室。EDTA抗凝血在血液分析仪上,白细胞系统及白细胞分类均可正常检出,血红蛋白结果也正常,但却出现红细胞计数与血红蛋白比值严重不符的情况,工作人员肉眼可看到小的凝集,将标本放置37℃水浴10min后计数正常。

病例:真的是颅内感染?真相只有一个!

病例摘要 患者韦某,男:65岁。患者家属代诉于入院前2小时发现患者昏迷不醒,呼之不应,伴有呕吐胃内容物,无抽搐,无大小便失禁,无气促、呼吸困难,于2018年8月26日来我院就诊,急诊行头颅CT检查后,拟“脑干出血并破入脑室”收入ICU。

幽门螺杆菌为什么会“死灰复燃”,如何“斩草除根”?只需把好这两关!

同学们好,我—幽门螺杆菌之前和大家说了为什么我被别人说成是一朵奇葩,你感染了我后,有可能没什么感觉,也有可能会查出来有一些胃病。 只有在消化性溃疡和MALT淋巴瘤的时候是一定要杀了我,其他时候还是和医生商量下再说。如果真的要杀我,一定要选对药、吃对药,否则就可能杀不了我。但为什么明明杀了我,但过段时间我又来了呢?

动脉血和静脉血常规生化项目是否存在差异?

一、背景&目的 ICU重症患者应用的有创性治疗和检测较多,因此动脉留置导管在ICU病房应用非常广泛,可以为危重病患者提供迅速、直接、准确的血压数据,并可以频繁抽取动脉血标本进行血气分析。

妊娠子痫前期凶险,千万别忘做这个检验

子痫前期(Preeclampsia, PE)是妊娠期特有的全身性多系统综合征,以高血压和蛋白尿为主要临床表现,患病率达2-8%,是孕产妇和胎儿死亡重要原因,约占孕产妇死亡原因的10~15%]。

JCLA:Taqman基因分型调用错误的特点及影响因素

Taqman荧光探针常用于单核苷酸多态性基因分型。然而,有关其调用误差的特点及影响因素尚不清楚。 本研究基于孟德尔遗传对Taqman基因分型的调用误差进行系统评价。Taqman探针检测了419个家系的22个snp基因型。统计每个单核苷酸多态性和家系的孟德尔遗传错误。采用聚类分析方法研究Taqman探针与DNA样品的相容性。结果显示,一方面,所有snp均存在误差;误差范围从4到33,中位数为1

Baidu
map
Baidu
map
Baidu
map